The MD simulations in the current study indicate that both CLQ-OH and ATM may block SARS-CoV2 binding to gangliosides via mirror competitive mechanisms. ATM, which has some molecular similarity with GM1 sugar, can thus occupy the ganglioside-binding domain of the spike protein and neutralize virus binding to lipid rafts. CLQ-OH covers the ganglioside surface, and thus also prevents virus-membrane interaction through a complementary mechanism. Each of these drugs might be efficient alone to block virus attachment, ATM through virus binding, CLQ-OH through ganglioside binding. As both drugs interfere with the same mechanism but with distinct molecular targets, they are expected to work together in synergy, as indicated by recent clinical data [3].